ABOUT IGBA

• Founded in March 1997 as the International Generic Pharmaceutical Alliance
• Renamed International Generic and Biosimilar Medicines Association (IGBA) in September 2015
• Legally incorporated in Geneva, Switzerland
• Maintains constant dialogue with the WHO, WTO, WIPO, ICH and other national, regional and international bodies
MEMBERS

• IGBA is committed to promoting generic and biosimilar medicines worldwide, and consists of the following associations:

  • Canadian Generic Pharmaceutical Association (CGPA-Canada)
  • Association for Accessible Medications (AAM-United States)
  • Japan Generic Medicines Association (JGA-Japan)
  • Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
  • Medicines for Europe (Europe)
  • Generic and Biosimilar Medicines of Southern Africa (GBM)
  • Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)

The generic and biosimilar medicines associations of Australia, Brazil, Malaysia and Mexico are Associate Members.

• In addition, IGBA includes:
  – Biosimilars Canada
  – Biosimilars Council (AAM Division)
  – Biosimilar Medicines Group (Medicines for Europe Sector Group)
IGBA Goals

• Promote regulatory cooperation and convergence for approval of generic and biosimilar medicines
• Promote the widest possible access of medicines globally with high quality, safety and efficacy
• Promote intellectual property regimes which foster innovation and allow timely launch of generic and biosimilar medicines, while supporting fair competition and preventing risks of IP abuses globally
• Support and co-operate with international bodies and initiatives including the WHO, WTO, WIPO, ICH, IGDRP, IPRF, etc.
• Support parties in international and regional agreement negotiations to remove barriers and facilitate the registration and supply of generic and biosimilar medicines
• Foster sustainability of medicine manufacturers in the interests of healthcare systems and patients
• Advance better access to generic and biosimilar medicines globally by organizing international conferences for the industry, stakeholders and regulators
IGBA and ICH

- Generic Industry Scientific experts have served on ICH Expert Working Groups since inception of IGPA in 1997 as Interested Parties
- IGBA was accepted as an Industry Member of the ICH Assembly in June 2016 following the ICH Reorganization in 2015
- IGBA is represented by Experts on 7 current ICH Expert Working Groups
- IGBA hopes to be elected to serve on the Management Committee of ICH in the near future
IGBA Companies – Our Position

• IGBA Member Companies are staffed with the best scientific talent and brightest minds in the global generic pharmaceutical industry.
• IGBA Member Companies develop, register, manufacture, and distribute medicines in virtually every country in the world.
• IGBA Member Companies are ready, willing, and able to deploy the most advanced scientific methods for development of their products.
• IGBA Member Companies would like to partner with the Drug Regulatory Authorities from around the world to establish harmonized regulatory standards and pathways for generic and biosimilar medicines using state-of-the-art scientific methodologies that result in the widest access to affordable quality medicines.